We sought to investigate the efficacy and safety of the oral CRTH2 antagonist BI 671800 ( 50 , 200 , and 400 mg twice daily ) , fluticasone propionate nasal spray ( 200 g once daily ) , or oral montelukast ( 10 mg once daily ) administered for 2 weeks in patients with SAR .